A reduction-sensitive lipophilic dihydroartemisinin prodrug in a self-microemulsifying drug delivery system for treating breast cancer lung metastasis via intestinal lymphatic transport
Bin Zheng, Cuiping He, Fengye Zhao, Ran Li, Ziyi Zhang, Xiaojie Chen, Minfei Shi, Beibei He, Rongrong Wang, Guolian Ren, Shuqiu Zhang, Shuang Yang · 2026
Read A reduction-sensitive lipophilic dihydroartemisinin prodrug in a self-microemulsifying drug delivery system for treating breast cancer lung metastasis via intestinal lymphatic transport by Bin Zheng, Cuiping He, Fengye Zhao, Ran Li, Ziyi Zhang, Xiaojie Chen, Minfei Shi, Beibei He, Rongrong Wang, Guolian Ren, Shuqiu Zhang, Shuang Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13156721.txt.
Description
Bin Zheng and co-authors route a malaria-derived drug through the gut's lymph path to reach lung tumours. Their 2026 study treats breast cancer that has spread to the lungs. The drug is a fat-loving prodrug of dihydroartemisinin, packed in a self-emulsifying mix taken by mouth.
The prodrug loaded better into the oily mix and released its payload where reducing conditions run high. Gut cells took it in and passed it along the fat transport route. Levels in lymph nodes rose, and blood exposure beat the plain drug many times over. In mice it fought both breast tumours and lung spread without clear harm. Immune calm inside the tumours eased too.
Catalog record
| CREATOR | Bin Zheng, Cuiping He, Fengye Zhao, Ran Li, Ziyi Zhang, Xiaojie Chen, Minfei Shi, Beibei He, Rongrong Wang, Guolian Ren, Shuqiu Zhang, Shuang Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 110 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |